Antihypertensive Trial Design ALLHAT
|
|
- Alyson Walters
- 5 years ago
- Views:
Transcription
1 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes of Health The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial () The Collaborative Research Group National Heart, Lung, and Blood Institute Sponsored by the National Heart, Lung, and Blood Institute (NHLBI) JAMA. 2002;288:
2 2 Antihypertensive Trial Design Randomized, double-blind, multi-center clinical trial Determine whether occurrence of fatal CHD or nonfatal MI is lower for high-risk hypertensive patients treated with newer agents (CCB, ACEI, alpha-blocker) compared with a diuretic 42,418 high-risk hypertensive patients 55 years
3 3 Secondary Objectives: Subgroups Pre-specified Age 65+ Women African-Americans Diabetic patients Post-hoc Baseline CHD
4 4 Secondary Outcomes All-cause mortality Stroke Combined CHD nonfatal MI, CHD death, coronary revascularization, hospitalized angina Combined CVD combined CHD, stroke, lower extremity revascularization, treated angina, fatal / hospitalized / treated CHF, hospitalized or outpatient PAD Other renal (reciprocal serum creatinine, ESRD, estimated GFR) and cancer
5 5 Sites in 623 clinical sites United States, Canada, Puerto Rico, US Virgin Islands VA, private & group general medicine practices, community health centers, HMOs, specialty practices Variety of research experience
6 6 High-risk hypertensive patients Randomized Design Consent / Randomize (42,418) of Amlodipine Chlorthalidone Doxazosin Lisinopril Eligible for lipidlowering Not eligible for lipid-lowering Consent / Randomize (10,355) Pravastatin Usual care Follow for CHD and other outcomes until death or end of study (up to 8 yr).
7 7 Inclusion Criteria for Antihypertensive Trial Age/sex: men and women aged > 55 years BP eligibility: Untreated systolic and/or diastolic hypertension ( 140/90 mm Hg but 180/110 mm Hg at two visits) Treated hypertension 160/100 mm Hg on 1-2 antihypertensive drugs at Visit 1 180/110 mm Hg at Visit 2, when medication may have been partially withdrawn No washout period was required in.
8 8 Inclusion Criteria: Risk Factors At least one of the following: Myocardial infarction or stroke: at least 6 months old, or age-indeterminate History of revascularization procedure Major ST segment depression or T-wave inversion Other documented ASCVD
9 9 Inclusion Criteria: Risk Factors At least one of the following (cont.) Type 2 diabetes mellitus HDL cholesterol < 35 mg/dl on any 2 or more determinations in past 5 years Left ventricular hypertrophy (past 2 years) ECG, or echo (septum + posterior wall thickness 25 mm) Current cigarette smoking
10 10 Major Exclusion Criteria MI, stroke, or angina within 6 months Symptomatic CHF or ejection fraction < 35% Known renal insufficiency - creatinine 2 mg/dl Requiring diuretics, CCB, ACEI, or alpha blockers for reasons other than hypertension
11 11 Sample Size Assumptions & Statistical Methods 83% power to detect 16% reduction in risk for primary outcome 2-sided α=.0178 (z=2.37) Accounts for multiple comparisons Analysis according to intent to treat Cumulative event rates Kaplan-Meier Differences between event curves - Log-rank tests & Cox proportional hazards (PH) model PH assumption tested by log-log plots, tests with treatment by time interaction If violated, 2 x 2 table used
12 12 Step 1 Treatment Protocol Step 1 Agent Initial Dose* Dose 1* Dose 2* Dose 3* Chlorthalidone Amlodipine Lisinopril Doxazosin * mg/day
13 13 Step Up Treatment Protocol Step 2 Agents: Dose 1* Dose 2* Dose 3* Reserpine 0.05 qd 0.1 qd 0.2 qd or 0.1 qod Clonidine (oral) 0.1 bid 0.2 bid 0.3 bid Atenolol 25 qd 50 qd 100 qd Step 3 Agent: Hydralazine 25 bid 50 bid 100 bid *All doses in mg
14 14 Safety Outcomes Angioedema Hospitalization for gastrointestinal bleeding Records from the VA hospitalization database Records from the Center for Medicare & Medicaid Services (CMS) database (participants age 65 or older)
15 15 Decision to Drop an Arm January 24, 2000 NHLBI Director accepts the recommendation of an independent review group to terminate doxazosin arm Futility of finding a significant difference for primary outcome Statistically significant 25 percent higher rate of major secondary endpoint, combined CVD outcomes
16 16 Cumulative Event Rate C: 15,268 D: 9,067 Cardiovascular Disease Rel Risk 1.25 doxazosin 12,990 7,382 95% CI z = 6.77, p < chlorthalidone 9,443 5,285 Years of Follow-up 4,827 2,654 2,010 1,083 JAMA. 2000;283:
17 17 Cumulative Event Rate C: 15,268 D: 9,067 Heart Failure Rel Risk 2.04 doxazosin 95% CI z = 10.95, p < Years of Follow-up chlorthalidone 9,541 5,531 2,427 13,644 5,457 3,089 1, , JAMA. 2000;283:
18 18 Comparison of Doxazosin with Chlorthalidone - Conclusions Doxazosin is not recommended as firstline therapy in hypertension. does not allow an assessment of the effect of doxazosin compared with placebo on the incidence of CVD. The use of doxazosin as a step-up drug for treating hypertension was not tested in this trial. These findings are likely to apply to all alpha-blockers. JAMA. 2000;283:
19 19 Baseline Characteristics Chlorthalidone 15,255 Amlodipine 9,048 Lisinopril 9,054 Mean SBP/DBP 146 / / / 84 Treated (90%) 145 / / / 84 Untreated (10%) 156 / / / 89 Mean age, y Black, % Women, % Current smoking % History of CHD, % Type 2 diabetes, %
20 20 On Step 1 or Equivalent Treatment by Antihypertensive Treatment Group % Year 2 Years 3 Years 4 Years 5 Years Chlor Aml Lis
21 Full Crossovers by Antihypertensive Treatment Group Chlorthalidone: not on assigned medicine or open-label diuretic, but on open-label calcium channel blocker or ACE-inhibitor Amlodipine: not on assigned medicine or open-label calcium channel blocker, but on open-label diuretic Lisinopril: not on assigned medicine or open-label ACE-inhibitor, but on open-label diuretic % Year 2 Years 3 Years 4 Years 5 Years Chlor Amlodipine Lisinopril
22 22 On Step 2 or Step 3 Treatment by Antihypertensive Treatment Group % Year 2 Years 3 Years 4 Years 5 Years Chlor Aml Lis
23 23 BP Results by Treatment Group Chlorthalidone Amlodipine Lisinopril C A L BL M Y Y Y C A L BL M Y Y Y mm Hg BP 140 mm Hg BP Years Years Compared to chlorthalidone: SBP significantly higher in the amlodipine group (~1 mm Hg) and the lisinopril group (~2 mm Hg). Compared to chlorthalidone: DBP significantly lower in the amlodipine group (~1 mm Hg).
24 24 Biochemical Results Serum cholesterol- mg/dl, mean (SD) Baseline 4 Years Serum potassium mmol/l, mean (SD) Baseline 4 Years Estimated GFR ml/min/1.73m 2,mean (SD) Baseline 4 Years * p<.05 compared to chlorthalidone Ann Intern Med. 1999;130: Chlorthalidone (43.8) (42.1) 4.3 (0.7) 4.1 (0.7) 77.6 (19.7) 70.0 (19.7) Amlodipine (44.1) (41.0)* 4.3 (0.7) 4.4 (0.7)* 78.0 (19.7) 75.1 (20.7)* Lisinopril (42.4) (40.6)* 4.4 (0.7)* 4.5 (0.7)* 77.7 (19.9) 70.7 (20.1)*
25 25 Biochemical Results Fasting Glucose mg/dl Chlorthalidone Amlodipine Lisinopril Total mean (SD) Baseline (58.3) (57.0) (56.1) 4 Years (55.6) (52.0) (51.3)* Among baseline nondiabetics with baseline <126 mg/dl mean (SD) Baseline 93.1 (11.7) 93.0 (11.4) 93.3 (11.8) 4 Years (28.5) (27.7) (19.5)* Diabetes Incidence (follow-up fasting glucose 126 mg/dl) 4 Years 11.6% 9.8%* 8.1%* *p<.05 compared to chlorthalidone
26 26 Follow-Up Chlorthalidone Amlodipine Lisinopril Randomized 15,255 9,048 9,054 Known alive 12,530 (82.1%) 7,479 (82.7%) 7,412 (81.9%) Confirmed deaths 2,203 (14.4%) 1,256 (13.9%) 1,314 (14.5%) Deaths pending confirmation 103 (0.7%) 55 (0.6%) 52 (0.6%) Lost 339 (2.2%) 200 (2.2%) 218 (2.4%) Refused 80 (0.5%) 58 (0.6%) 58 (0.6%) Person-years 99% 99% 99% (% obs/exp)
27 27 Cumulative CHD Event Rate Cumulative Event Rates for the Primary Outcome (Fatal CHD or Nonfatal MI) by Treatment Group A/C L/C RR (95% CI) 0.98 ( ) 0.99 ( ) Chlorthalidone Amlodipine Lisinopril p value Years to CHD Event Number at Risk: Chlorthalidone 15,255 14,477 13,820 13,102 11,362 6,340 2, Amlodipine 9,048 8,576 8,218 7,843 6,824 3,870 1, Lisinopril 9,054 8,535 8,123 7,711 6,662 3,832 1,
28 28 Nonfatal MI + CHD Death Subgroup Comparisons RR (95% CI) Total 0.98 (0.90, 1.07) Age < (0.85, 1.16) Age>= (0.88, 1.08) Men 0.98 (0.87, 1.09) Women 0.99 (0.85, 1.15) Black 1.01 (0.86, 1.18) Non-Black 0.97 (0.87, 1.08) Diabetic 0.99 (0.87, 1.13) Non-Diabetic 0.97 (0.86, 1.09) Amlodipine Better Chlorthalidone Better Total 0.99 (0.91, 1.08) Age < (0.81, 1.12) Age >= (0.91, 1.12) Men 0.94 (0.85, 1.05) Women 1.06 (0.92, 1.23) Black 1.10 (0.94, 1.28) Non-Black 0.94 (0.85, 1.05) Diabetic 1.00 (0.87, 1.14) Non-Diabetic 0.99 (0.88, 1.11) Lisinopril Better Chlorthalidone Better
29 29 Cumulative Event Rates for Stroke by Treatment Group.1 RR (95% CI) p value.08 A/C L/C 0.93 ( ) 1.15 ( ) Cumulative Stroke Rate Chlorthalidone Amlodipine Lisinopril Years to Stroke Number at risk: Chlor 15,255 14,515 13,934 13,309 11,570 6,385 3, Amlo 9,048 8,617 8,271 7,949 6,937 3,845 1, Lisin 9,054 8,543 8,172 7,784 6,765 3,891 1,
30 30 Stroke Subgroup Comparisons RR (95% CI) Total 0.93 (0.82, 1.06) Age < (0.73, 1.19) Age >= (0.81, 1.08) Men 1.00 (0.85, 1.18) Women 0.84 (0.69, 1.03) Black 0.93 (0.76, 1.14) Non-Black 0.93 (0.79, 1.10) Diabetic 0.90 (0.75, 1.08) Non-Diabetic 0.96 (0.81, 1.14) Amlodipine Better Chlorthalidone Better Total 1.15 (1.02, 1.30) Age < (0.97, 1.52) Age >= (0.98, 1.30) Men 1.10 (0.94, 1.29) Women 1.22 (1.01, 1.46) Black 1.40 (1.17, 1.68) Non-Black 1.00 (0.85, 1.17) Diabetic 1.07 (0.90, 1.28) Non-Diabetic 1.23 (1.05, 1.44) Lisinopril Better Chlorthalidone Better P =.01 for interaction
31 Cumulative Event Rates for All-Cause Mortality by Treatment Group A/C L/C RR (95% CI) 0.96 ( ) 1.00 ( ) p value Cumulative Mortality Rate Chlorthalidone Amlodipine Lisinopril Years to Death Number at risk: Chlor 15,255 14,933 14,564 14,077 12, , Amlo 9,048 8,847 8,654 8,391 7,442 4,312 2, Lisin 9,054 8,853 8,612 8,318 7,382 4,304 2,
32 32 All-Cause Mortality Subgroup Comparisons RR (95% CI) Total 0.96 (0.89, 1.02) Age < (0.83, 1.10) Age >= (0.88, 1.03) Men 0.95 (0.87, 1.04) Women 0.96 (0.86, 1.07) Black 0.97 (0.87, 1.09) Non-Black 0.94 (0.87, 1.03) Diabetic 0.96 (0.87, 1.07) Non-Diabetic 0.95 (0.87, 1.04) Amlodipine Better Chlorthalidone Better Total 1.00 (0.94, 1.08) Age < (0.81, 1.08) Age >= (0.95, 1.12) Men 0.99 (0.91, 1.08) Women 1.02 (0.91, 1.13) Black 1.06 (0.95, 1.18) Non-Black 0.97 (0.89, 1.06) Diabetic 1.02 (0.91, 1.13) Non-Diabetic 1.00 (0.91, 1.09) Lisinopril Better Chlorthalidone Better
33 33 Cumulative Event Rates for Combined CVD by Treatment Group.5 RR (95% CI) p value A/C 1.04 ( ) 0.12 Cumulative Combined CVD Event Rate L/C 1.10 ( ) Chlorthalidone Amlodipine Lisinopril < Years to Combined CVD Event Number at risk: Chlor 15,255 13,752 12,594 11,517 9,643 5,167 2, Amlo 9,048 8,118 7,451 6,837 5,724 3,049 1, Lisin 9,054 7,962 7,259 6,631 5,560 3,011 1,
34 34 Combined CVD Subgroup Comparisons RR (95% CI) Total 1.04 (0.99, 1.09) Age < (0.94, 1.12) Age >= (0.99, 1.12) Men 1.04 (0.98, 1.11) Women 1.04 (0.96, 1.13) Black 1.06 (0.96, 1.16) Non-Black 1.04 (0.97, 1.10) Diabetic 1.06 (0.98, 1.15) Non-Diabetic 1.02 (0.96, 1.09) Amlodipine Better Chlorthalidone Better Total 1.10 (1.05, 1.16) Age < (0.97, 1.15) Age >= (1.06, 1.20) Men 1.08 (1.02, 1.15) Women 1.12 (1.03, 1.21) Black 1.19 (1.09, 1.30) Non-Black 1.06 (1.00, 1.13) Diabetic 1.08 (1.00, 1.17) Non-Diabetic 1.12 (1.05, 1.19) Lisinopril Better Chlorthalidone Better P =.04 for interaction
35 35 Cumulative Event Rates for Heart Failure by Treatment Group.15 A/C RR (95% CI) 1.38 ( ) p value <.001 L/C 1.19 ( ) <.001 Cumulative CHF Rate Chlorthalidone Amlodipine Lisinopril Years to HF Number at risk: Chlor 15,255 14,528 13,898 13,224 11,511 6,369 3, Amlo 9,048 8,535 8,185 7,801 6,785 3,775 1, Lisin 9,054 8,496 8,096 7,689 6,698 3,789 1,
36 36 Heart Failure Subgroup Comparisons RR (95% CI) Total 1.38 (1.25, 1.52) Age < (1.25, 1.82) Age >= (1.18, 1.49) Men 1.41 (1.24, 1.61) Women 1.33 (1.14, 1.55) Black 1.47 (1.24, 1.74) Non-Black 1.33 (1.18, 1.51) Diabetic 1.42 (1.23, 1.64) Non-Diabetic 1.33 (1.16, 1.52) Amlodipine Better Chlorthalidone Better Total 1.20 (1.09, 1.34) Age < (1.01, 1.50) Age >= (1.06, 1.35) Men 1.19 (1.03, 1.36) Women 1.23 (1.05, 1.43) Black 1.32 (1.11, 1.58) Non-Black 1.15 (1.01, 1.30) Diabetic 1.22 (1.05, 1.42) Non-Diabetic 1.20 (1.04, 1.38) Lisinopril Better Chlorthalidone Better
37 37 Overall Conclusions Because of the superiority of thiazide-type diuretics in preventing one or more major forms of CVD and their lower cost, they should be the drugs of choice for first-step antihypertensive drug therapy.
38 38 Other Conclusions Neither amlodipine (representing CCB) nor lisinopril (representing ACEI) was superior to chlorthalidone (representing thiazide-type diuretics) in preventing major coronary events or increasing overall survival. Although chlorthalidone did not differ from amlodipine in overall CVD event prevention, it was superior to amlodipine (by about onefourth) in preventing heart failure, overall and for hospitalized or fatal cases.
39 39 Other Conclusions Chlorthalidone was superior to lisinopril in preventing aggregate CV events, principally stroke, HF, angina, and coronary revascularization Chlorthalidone was superior to doxazosin (representing alpha-blockers) in preventing CV events, including both HF and other CVD.
40 40 Other Conclusions Given the large sample size, almost all biochemical differences between treatment groups at 4 years were statistically significant. Total cholesterol 1-2 mg/dl higher in chlorthalidone compared to amlodipine and lisinopril. Serum potassium mmol/l lower in chlorthalidone compared to amlodipine and lisinopril. Potassium <3.5 mmol/l 6-8% higher among those randomized to chlorthalidone Fasting glucose 3 mg/dl higher in chlorthalidone than amlodipine group, 5 mg/dl higher in chlorthalidone than lisinopril group.
41 41 Other Conclusions Among nondiabetic participants, incidence of fasting glucose 126 mg/dl at 4 years was 1.8% higher in chlorthalidone vs amlodipine, and 3.5% higher in chlorthalidone vs lisinopril. Estimated GFR decreased by 7-8 units at 4 years in chlorthalidone and lisinopril arms, but decreased only by about 3 units in the amlodipine arm. Overall, metabolic differences did not translate into more adverse cardiovascular events, or into higher all-cause mortality, with chlorthalidone.
42 42 Further Conclusions: Amlodipine versus Chlorthalidone Drug tolerance and blood pressure control were similar (and high): The percent of participants who remained on the assigned drug or another of the same class was essentially identical (80% of those attending the 5- year visit) Mean SBP averaged about 1 mm Hg higher, and mean DBP about 1 mm Hg lower, in the amlodipine group BP control averaged about 2% better in the chlorthalidone group, reaching 68% after 5 years
43 43 Further Conclusions: Amlodipine versus Chlorthalidone There were no differences for other secondary outcomes: Cardiovascular stroke, angina, coronary revascularization, peripheral arterial disease End stage renal disease Cancer incidence and mortality Hospitalization for gastrointestinal bleeding (in a subset of the cohort) All-cause mortality
44 44 Further Conclusions: Amlodipine versus Chlorthalidone Results for all cited outcomes were consistent for major (pre-specified) subgroups: Men and women Black and nonblack participants Older and younger participants (<65 and 65+) Diabetic and non-diabetic participants
45 45 Further Conclusions: Lisinopril versus Chlorthalidone Drug tolerance and blood pressure control were better with chlorthalidone, especially for black patients: The percent of participants remaining on lisinopril or another ACEI averaged about 5-6% less than participants assigned to the diuretic About 6-8% more of the participants in the lisinopril group than those in the chlorthalidone group required additional antihypertensive drugs
46 46 Further Conclusions: Lisinopril versus Chlorthalidone Mean SBP averaged about 2 mm Hg higher in the lisinopril than the chlorthalidone group (4 mm Hg for blacks); mean DBPs were equivalent BP control averaged about 4-7% better in the chlorthalidone group Of patients in the lisinopril group who remained on an ACEI, 19% were also on a diuretic at 5 years
47 47 Further Conclusions: Lisinopril versus Chlorthalidone There were no differences for other secondary outcomes peripheral arterial disease end stage renal disease cancer incidence and mortality all-cause mortality
48 48 Further Conclusions: Lisinopril versus Chlorthalidone Results were consistent for all outcomes by age, gender, race, and diabetic status, except for stroke and CVD, where there was significant heterogeneity by race (p=.01 and p=.04, respectively) Among black participants assigned to lisinopril, the stroke rate was increased 40% compared to the chlorthalidone group. (No difference among nonblack participants.) The combined CVD rate was increased 19% in blacks and by 6% in whites. Angiodema, a rare adverse effect, was more frequent with lisinopril, especially in blacks
49 49 Antihypertensive Trial: Implications Diuretics should be the drug of choice for first step therapy of hypertension For the patient who cannot take a diuretic (which should be an unusual circumstance), CCB s and ACEI s may be considered. Most hypertensive patients require more than one drug. Diuretics should generally be part of the antihypertensive regimen. Lifestyle advice should also be provided.
50 50 Angioedema Total Blacks Nonblacks Chlorthalidone 8 / 15,255 2 / 5,369 6 / 9, % <0.1% 0.1% Lisinopril 38 / 9, / 3, / 5, % 0.7% 0.3% p<.001 p<.001 p=.002 There were 3 cases (<0.1%) of angioedema in the amlodipine group (comparison to chlorthalidone not significant).
ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationRandomized Design of ALLHAT BP Trial
Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationTREATMENT AND COMPLICAtions
ORIGINAL CONTRIBUTION JAMA-EXPRESS Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and
More informationOutcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril JAMA. 2005;293:
ORIGINAL CONTRIBUTION Outcomes in Hypertensive and Patients Treated With, Amlodipine, and Lisinopril Jackson T. Wright, Jr, MD, PhD J. Kay Dunn, PhD Jeffrey A. Cutler, MD Barry R. Davis, MD, PhD William
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationALLHAT Investigators Report 10-Year Follow-up and Stand by Diuretics as First-Step Antihypertensive Treatment
1 sur 5 21/11/2009 07:26 www.medscape.com Medscape Medical News from the: American Heart Association (AHA) 2009 Scientific Sessions This coverage is not sanctioned by, nor a part of, the American Heart
More informationALLHAT. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationSponsored by the National Heart, Lung, and Blood Institute (NHLBI)
1 U.S. Department of Health and Human Services The Hypertension, Detection, and Follow-up Program (HDFP) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) National
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationDrug-Induced Diabetes May Not Be Harmful But Should Be Prevented. Jeffrey A. Cutler, MD, MPH
Drug-Induced Diabetes May Not Be Harmful But Should Be Prevented Jeffrey A. Cutler, MD, MPH Overview Focus on thiazide-like diuretics (not BB) Diuretic-induced versus diureticassociated diabetes Role of
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationFirst line treatment of primary hypertension
First line treatment of primary hypertension Dr. Vijaya Musini Assistant Professor, Dept. Anesthesiology, Pharmacology and Therapeutics Manager, Drug Assessment Working Group Therapeutics Initiative Editor,
More informationJackson T. Wright, Jr. MD, PhD
DIFFERENTIAL EFFECTS OF BLOOD PRESSURE MEDICATIONS IN BLACK PATIENTS Jackson T. Wright, Jr. MD, PhD Professor of Medicine Program Director, WT Dahms MD Clinical Research Unit Clinical and Translational
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationThe Antihypertensive and Lipid-Lowering Treatment to
Scientific Contributions Diuretic Versus -Blocker as First-Step Antihypertensive Therapy Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) ALLHAT
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationImproving Medical Statistics and Interpretation of Clinical Trials
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationThe Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationBLOOD PRESSURE-LOWERING TREATMENT
BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING
More informationHYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More information2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines
Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationHypertension Management in Diabetic Patients
Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension
More information